Teva Women's Health, Inc. (TEVA) to Present New Data at the 61st Annual Meeting of the American Congress of Obstetricians and Gynecologists
5/6/2013 9:19:09 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Teva Women’s Health, a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced new data for the oral contraceptives (OC) QuartetteTM (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets and an investigational 28-day OC regimen (150 mcg desogestrel (DSG)/20 mcg ethinyl estradiol (EE) for 21 days, followed by 7 days of 10 mcg EE) will be featured at the 61st Annual Meeting of the American Congress of Obstetricians and Gynecologists (ACOG). The meeting, held in New Orleans from May 4 – 8, 2013 features three company-sponsored posters.
Help employers find you! Check out all the jobs and post your resume.
comments powered by